FDA Inspection
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLCWyeth BioPharma Division of Wyeth Pharmaceuticals LLC – FDA Inspection, Jan 18, 2019
Record Details
This FDA Inspection record concerns Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC, with an inspection on January 18, 2019, issued by the New England District Office, covering human drugs.
- Inspection Date
- January 18, 2019
- Product Type
- Human Drugs
- Person
- Maxwell L. Van Tassell (Issuing Officer)
View Company Profile
ID · 9be04658-5d52-4b10-908c-17745d59a8c3
Inspection Facts
- Inspection number
- 1076904
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
16| Date | Classification | Office | Project area |
|---|---|---|---|
| August 6, 2026 | Not classified | New England District Office | |
| April 8, 2026 | Not classified | New England District Office | |
| February 11, 2026 | NAI | Human Cellular, Tissue, and Gene Therapies | |
| October 13, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 19, 2023 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
- FDA Inspection 1331288 - 2026-08-06
- FDA Inspection 1311392 - 2026-04-08
- FDA Inspection 1304580 - 2026-02-11
- FDA Inspection 1223617 - 2023-10-13
- FDA Inspection 1218069 - 2023-09-19
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.